Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 9/20 | 0.51 |
| ▸ | RET | P07949 | 6/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667431 | 1.00 | PTPN11 (0.51) | PTPN11RETHDAC3HDAC4HDAC1 | |
| SCHEMBL22389898 | 0.88 | PTPN11 (0.55) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16926933 | 0.87 | PTPN11 (0.64) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29710130 | 0.87 | PTPN11 (0.64) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29771167 | 0.87 | PTPN11 (0.51) | PTPN11 | |
| SCHEMBL22389872 | 0.87 | PTPN11 (0.52) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22389873 | 0.87 | PTPN11 (0.51) | PTPN11 | |
| SCHEMBL31318780 | 0.87 | PTPN11 (0.52) | PTPN11HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22389957 | 0.86 | PTPN11 (0.69) | PTPN11 | |
| SCHEMBL31318790 | 0.86 | PTPN11 (0.69) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795483-B | Carboxamide-pyrimidine derivatives as SHP2 antagonists | 默克专利有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-20220362244-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | PTPN5, PTPN2, PTPN1 | PTPN11 5/4885RET 60/4885HDAC3 760/4885 |
| US-20220362244-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | PTPN5, PTPN2, PTPN1 | PTPN11 5/4885RET 60/4885HDAC3 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.